Shopping cart

Subtotal: $4398.00

View cart Checkout

Magazines cover a wide subjects, including not limited to fashion, lifestyle, health, politics, business, Entertainment, sports, science,

Recent Posts

Blog Image

Fitness: Your journey to Better, stronger you.

21 June, 2023
Blog Image

Embrace the game Ignite your sporting

22 June, 2023
Blog Image

Revolutionizing lives Through technology

23 June, 2023
Blog Image

Enjoy the Virtual Reality embrace the

25 June, 2023
ads ads

Mankind Pharma IPO subscribed 15.32 times

2025-04-03
Blog Image

Mumbai: The ₹4,326-crore initial share sale of Mankind Pharma, the biggest in the last year, was subscribed 15.32 times on the final day of bidding Thursday. Bids were received for 429.5 million equity shares against an offer size of 28 million shares.The IPO, which is an offer for sale (OFS), has been sold in the price band of ₹1,024-1,080.This will be one of the largest public issues by a domestic drug manufacturer after the ₹6,480-crore IPO of Gland Pharma in 2020.

The qualified institutional buyers (QIB) category was subscribed 49 times, while the non-institutional investors or high net-worth individuals' portion was subscribed 3.8 times. However, the retail investor's portion was under-subscribed at 92 per cent.At the upper price band of ₹1,080, Mankind Pharma is valued at a price-to-earnings ratio of 30 times FY22 earnings and commands a market capitalisation of ₹44,000 crore. Post-IPO, the promoter will hold 78 per cent of the company, with 12 per cent held by existing PE investors.

Some of the sellers in the Mankind Pharma offer for sale include promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora and investors Cairnhill CIPEF, Cairnhill CGPE, Beige Limited, and Link Investment Trust. Ahead of its IPO, Mankind has raised '1,297 crore by allocating 12 million equity shares to 77 anchor investors. Subscribe to our newsletter to get latest insights & analysis.